Gilead and Galapagos' filgotinib OK'd in Europe
Investor Relations for NASDAQ and NYSE Public Companies Call OTC Tip Reporter 800-850-9305
Gilead and Galapagos' filgotinib OK'd in Europe for rheumatoid arthritis (NASDAQ:GILD)
Looking for additional coverage on your company? Businesses trading on the NASDAQ or New York Stock Exchange (NYSE) interested in media packages offered by OTC Tip Reporter can contact us today at 800-850-9305. Visit us online at otctipreporter.com and sign up for our newsletter.
-
Companies Trading on NASDAQ and NYSE Can Increase Visibility to Shareholders and Potential Investors with OTC Tip Reporter Media Packages